111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
SGLT2 抑制剂对 2 型糖尿病患者肿瘤发生风险的影响：一项回顾性队列研究
Authors Wang Y, Ding Y, Yan X, Yao J, Wang M, Li Z, Zhu Y
Received 22 August 2025
Accepted for publication 5 November 2025
Published 15 December 2025 Volume 2025:18 Pages 4587—4596
DOI https://doi.org/10.2147/DMSO.S550192
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Halis Akturk
Yuzhe Wang,1,* Yusen Ding,2,* XiangLong Yan,3 Jia Yao,2 Meiling Wang,2 Zhen Li,2 Yamei Zhu1
1Special Needs Ward 1, Qingdao Endocrine and Diabetes Hospital, Shandong, 266011, People’s Republic of China; 2Department of Diabetes and Peripheral Vascular Disease Surgery, Qingdao Endocrine and Diabetes Hospital, Shandong, 266011, People’s Republic of China; 3Department 5 of Oncology, Xi ‘an International Medical Center Hospital, Shaanxi, 710100, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yamei Zhu, Special Needs Ward 1, Qingdao Endocrine and Diabetes Hospital, No. 690, Hefei Road, Shibei District, Qingdao City, Shandong Province, 266011, People’s Republic of China, Tel +86-0532-58780626, Email y0gg4z@163.com
Aim: To assess the association between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and the risk of tumor development and survival outcomes in patients with type 2 diabetes.
Methods: This retrospective cohort study included 350 patients with type 2 diabetes treated at our institution between January 2021 and January 2025. Patients were categorized into an observation group (n = 189) receiving SGLT2 inhibitors and a control group (n = 161) treated with other antidiabetic medications. Clinical characteristics, glycemic control, cumulative drug exposure, and tumor incidence (lung, colorectal, prostate, breast, bladder, and hepatic cancers) were analyzed. Kaplan–Meier methods were used to evaluate cancer incidence and mortality outcomes.
Results: Overall tumor incidence was significantly lower in the SGLT2 inhibitor group than in the control group (P < 0.001), mainly due to reduced lung (P = 0.018) and ovarian cancers (P = 0.017). Smoking, alcohol consumption, and poor glycemic control were associated with higher overall and site-specific tumor risks. The SGLT2 inhibitor group showed better metabolic profiles, with lower FBG, HbA1c, LDL, TC, TG, and higher HDL levels (all P < 0.05), as well as improved renal function indicated by lower BUN and creatinine and higher eGFR (all P < 0.001). Kaplan–Meier analysis demonstrated significantly longer progression-free and overall survival in the SGLT2 inhibitor group (both P < 0.01).
Conclusion: SGLT2 inhibitors reduced overall tumor risk, especially lung and ovarian cancers, and improved metabolic and survival outcomes in type 2 diabetes.
Keywords: diabetes medication, tumor development, SGLT2 inhibitors
1Special Needs Ward 1, Qingdao Endocrine and Diabetes Hospital, Shandong, 266011, People’s Republic of China; 2Department of Diabetes and Peripheral Vascular Disease Surgery, Qingdao Endocrine and Diabetes Hospital, Shandong, 266011, People’s Republic of China; 3Department 5 of Oncology, Xi ‘an International Medical Center Hospital, Shaanxi, 710100, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yamei Zhu, Special Needs Ward 1, Qingdao Endocrine and Diabetes Hospital, No. 690, Hefei Road, Shibei District, Qingdao City, Shandong Province, 266011, People’s Republic of China, Tel +86-0532-58780626, Email y0gg4z@163.com
Aim: To assess the association between sodium-glucose cotransporter 2 (SGLT2) inhibitor use and the risk of tumor development and survival outcomes in patients with type 2 diabetes.
Methods: This retrospective cohort study included 350 patients with type 2 diabetes treated at our institution between January 2021 and January 2025. Patients were categorized into an observation group (n = 189) receiving SGLT2 inhibitors and a control group (n = 161) treated with other antidiabetic medications. Clinical characteristics, glycemic control, cumulative drug exposure, and tumor incidence (lung, colorectal, prostate, breast, bladder, and hepatic cancers) were analyzed. Kaplan–Meier methods were used to evaluate cancer incidence and mortality outcomes.
Results: Overall tumor incidence was significantly lower in the SGLT2 inhibitor group than in the control group (P < 0.001), mainly due to reduced lung (P = 0.018) and ovarian cancers (P = 0.017). Smoking, alcohol consumption, and poor glycemic control were associated with higher overall and site-specific tumor risks. The SGLT2 inhibitor group showed better metabolic profiles, with lower FBG, HbA1c, LDL, TC, TG, and higher HDL levels (all P < 0.05), as well as improved renal function indicated by lower BUN and creatinine and higher eGFR (all P < 0.001). Kaplan–Meier analysis demonstrated significantly longer progression-free and overall survival in the SGLT2 inhibitor group (both P < 0.01).
Conclusion: SGLT2 inhibitors reduced overall tumor risk, especially lung and ovarian cancers, and improved metabolic and survival outcomes in type 2 diabetes.
Keywords: diabetes medication, tumor development, SGLT2 inhibitors